Who makes Placebo (for CKD-331)?

Placebo (for CKD-331) is developed by Chong Kun Dang Pharmaceutical.

What development phase is Placebo (for CKD-331) in?

Placebo (for CKD-331) is in Phase 3.

Last reviewed 2026-04-23 · How we verify

Placebo (for CKD-331)

Chong Kun Dang Pharmaceutical · Phase 3 active Small molecule

Placebo is an inert substance with no active pharmacological mechanism.

At a glance

Generic name	Placebo (for CKD-331)
Sponsor	Chong Kun Dang Pharmaceutical
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Placebo serves as a control comparator in clinical trials and contains no active pharmaceutical ingredient. It is used to establish the efficacy and safety profile of the investigational drug CKD-331 by comparison against a non-therapeutic baseline. Any observed effects are attributed to natural disease progression, regression to the mean, or psychological factors rather than direct drug action.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Placebo (for CKD-331) CI brief — competitive landscape report
Placebo (for CKD-331) updates RSS · CI watch RSS
Chong Kun Dang Pharmaceutical portfolio CI